Skip to main content

ACEi, angiotensin-converting enzyme inhibitor; ADHF, acute decompensated heart failure; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; ARR, absolute risk reduction; BID, twice daily; BNP, brain natriuretic peptide; CI, confidence interval; HR, hazard ratio; KM, Kaplan–Meier; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NNT, number needed to treat; NYHA, New York Heart Association; OR, odds ratio; RR, relative reduction; RRR, relative risk reduction; SD, standard deviation; SBP, systolic blood pressure.

1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. McMurray JJV, Packer M, Desai AS, et al; on behalf of the PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16(7):817-825. doi:10.1002/ejhf
3. Kristensen SL, Martinez F, Jhund PS, et al. Geographic variations in the PARADIGM-HF heart failure trial. Eur Heart J. 2016;37(41):3167-3174. Nov 1;37(41):3167-3174. doi:10.1093/eurheartj/ehw226
4. Data on file. LCZ696 Clinical Study Report (CLCZ696B2314). Novartis Pharmaceuticals Corp; 2014.
5. Zile MR, Clagget BL, Prescott MF, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016;68(22):2425-2436. doi:10.1016/j.jacc.2016.09.931
6. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-1997. doi:10.1093/eurheartj/ehv186
7. Velazquez EJ, Morrow DA, DeVore AD, et al; for the PIONEER-HF Investigators. Angiotensin–receptor-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539-548. doi:10.1056/NEJMoa1812851
8. Morrow DA, Velazquez EJ, DeVore AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. Circulation. 2019;139(19):2285-2288. doi:10.1161/CIRCULATIONAHA.118.039331
9. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal–pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174. doi:10.1161/01.CIR.0000144310.04433.BE
10. DeVore AD, Braunwald E, Morrow DA, et al; PIONEER-HF Investigators. Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial. JAMA Cardiol. 2020;5(2):202-207. doi:10.1001/jamacardio.2019.4665. Accessed December 12, 2019. Supplementary material accessed at
11. Albert N, Bena J, Morrison S, et al. Clinical outcomes when utilizing sacubitril/valsartan vs. ACEi/ARB in patients with HF and ejection fractions spanning from reduced to preserved—a retrospective, parallel, multi-group study. Paper presented at: Heart Failure Society of America. September 10-13, 2021.
12. US Food and Drug Administration. Novartis cardiovascular and renal drugs advisory committee briefing document, December 15, 2020. ENTRESTO® (sacubitril/valsartan) for chronic heart failure and preserved ejection fraction. Accessed October 3, 2023.